Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Latest News about Eisai Co Ltd

Recent news which mentions Eisai Co Ltd

Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug
Tags Companies Pharmaceuticals Eisai Co Ltd
From CNBC.com News
Biogen tops estimates, raises profit guidance as Alzheimer's drug Leqembi gains traction
Tags Biotechnology Business News Earnings
From CNBC.com News
5 things to know before the stock market opens Monday
Tags Ford Motor Co Markets Investing
From CNBC.com News
Alzheimer's drug Leqembi promises to give patients more time, but they face a long road to treatment
Tags Business Health & Science Biotech and Pharmaceuticals
From CNBC.com News
Patients on Alzheimer's drug Leqembi see benefits over three years, Eisai study says
Tags Biotech and Pharmaceuticals Breaking news Science
From CNBC.com News
Older GLP-1 drug from Novo Nordisk may slow Alzheimer's disease progression by protecting the brain, study says
Tags Pharmaceuticals Companies Eisai Co Ltd
From CNBC.com News
European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, Eisai
Tags US: News Biogen Inc Biotechnology
From CNBC.com News
Jim Cramer says Eli Lilly isn't a 'one trick pony' after FDA advisers endorse its Alzheimer's drug
Tags stocks Business Eli Lilly and Co
From CNBC.com News
Biogen tops quarterly profit estimates as cost cuts take hold, Leqembi launch picks up
Tags Eisai Co Ltd Health care industry Pharmaceuticals
From CNBC.com News
Eli Lilly says FDA delays approval of Alzheimer's drug in surprise move
Tags Business Eli Lilly and Co Health & Science
From CNBC.com News
Healthy Returns: The launch of breakthrough Alzheimer’s drug Leqembi is off to a slow start
Tags Health & Science Health care industry Eisai Co Ltd
From CNBC.com News
Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapies
Tags Health care industry Eisai Co Ltd Pharmaceuticals
From CNBC.com News
Biogen drops controversial Alzheimer's drug Aduhelm to focus on Leqembi, experimental treatments
Tags Biotech and Pharmaceuticals Science Business
From CNBC.com News
Weight loss drugs, Alzheimer's treatments and gene editing: Enormous firsts defined 2023 in pharma
Tags Biotechnology Business News Biogen Inc
From CNBC.com News
Pfizer's twice-daily weight loss pill joins a long list of obesity drug flops
Tags Abbott Laboratories Business Eli Lilly and Co
From CNBC.com News
More convenient form of breakthrough Alzheimer's drug Leqembi shows promising results in study
Tags Eisai Co Ltd Health care industry Pharmaceuticals
From CNBC.com News
5 things to know before the stock market opens Tuesday
Tags Biogen Inc JPMorgan Chase & Co Meta Platforms Inc
From CNBC.com News
Eli Lilly expects FDA decision on Alzheimer's treatment donanemab by the end of the year
Tags Eli Lilly and Co Business Health & Science
From CNBC.com News
Medicare will pay for Alzheimer's drug Leqembi. What patients and doctors should know
Tags Health & Science Social issues U/S/ Economy
From CNBC.com News
Sales of Alzheimer’s drug Leqembi may be slow initially but could pick up in 2024
Tags Science Biotech and Pharmaceuticals Health & Science
From CNBC.com News
Stocks making the biggest moves midday: Rivian, Levi Strauss, Biogen, First Solar and more
Tags Economy stocks DraftKings Inc
From CNBC.com News
Japanese pharma Eisai slides 4% despite FDA approval for Alzheimer's drug
Tags Biogen Inc Biotech and Pharmaceuticals World Markets
From CNBC.com News
FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverage
Tags Social issues Health & Science Business
From CNBC.com News
FDA advisors to weigh whether Alzheimer's drug Leqembi should receive full approval
Tags Politics Disease outbreaks Business
From CNBC.com News
Bernie Sanders says price of Alzheimer's treatment is unconscionable, calls on HHS to take action
Tags Policy US Economy Biotech and Pharmaceuticals
From CNBC.com News
Alzheimer's treatment Leqembi could cost Medicare up to $5 billion per year, study estimates
Tags Biotech and Pharmaceuticals Policy Politics
From CNBC.com News
Bipartisan attorneys general call on Medicare to cover Alzheimer's treatments
Tags Eisai Co Ltd Health care industry Coronavirus
From CNBC.com News
Alzheimer’s patients may wait years to get treated with new drugs, putting them at risk of more severe disease
Tags Coronavirus Health care industry World News
From CNBC.com News
Alzheimer's: Medicare will cover Leqembi for all patients if FDA approves drug, CMS chief says
Tags Biotechnology Business News Biogen Inc
From CNBC.com News
Biogen isn't concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says
Tags Business News Biotechnology Alzheimer's disease
From CNBC.com News
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.